|
1
|
Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine.
|
Proc Natl Acad Sci U S A
|
2010
|
3.86
|
|
2
|
Downregulation of death-associated protein kinase 1 (DAPK1) in chronic lymphocytic leukemia.
|
Cell
|
2007
|
3.58
|
|
3
|
Combination chemoimmunotherapy with pentostatin, cyclophosphamide, and rituximab shows significant clinical activity with low accompanying toxicity in previously untreated B chronic lymphocytic leukemia.
|
Blood
|
2006
|
3.17
|
|
4
|
Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia.
|
Blood
|
2006
|
3.16
|
|
5
|
Phase III trial of fludarabine plus cyclophosphamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukemia: US Intergroup Trial E2997.
|
J Clin Oncol
|
2007
|
3.09
|
|
6
|
Select high-risk genetic features predict earlier progression following chemoimmunotherapy with fludarabine and rituximab in chronic lymphocytic leukemia: justification for risk-adapted therapy.
|
J Clin Oncol
|
2005
|
3.05
|
|
7
|
Relative value of ZAP-70, CD38, and immunoglobulin mutation status in predicting aggressive disease in chronic lymphocytic leukemia.
|
Blood
|
2008
|
2.72
|
|
8
|
Phase I study of decitabine alone or in combination with valproic acid in acute myeloid leukemia.
|
J Clin Oncol
|
2007
|
2.64
|
|
9
|
Guidelines for the development and incorporation of biomarker studies in early clinical trials of novel agents.
|
Clin Cancer Res
|
2010
|
2.44
|
|
10
|
Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions.
|
Blood
|
2004
|
2.39
|
|
11
|
A phase 1 and pharmacodynamic study of depsipeptide (FK228) in chronic lymphocytic leukemia and acute myeloid leukemia.
|
Blood
|
2004
|
2.37
|
|
12
|
Phase II study of flavopiridol in relapsed chronic lymphocytic leukemia demonstrating high response rates in genetically high-risk disease.
|
J Clin Oncol
|
2009
|
2.34
|
|
13
|
Clinical response and pharmacokinetics from a phase 1 study of an active dosing schedule of flavopiridol in relapsed chronic lymphocytic leukemia.
|
Blood
|
2008
|
2.22
|
|
14
|
Treatment of relapsed chronic lymphocytic leukemia by 72-hour continuous infusion or 1-hour bolus infusion of flavopiridol: results from Cancer and Leukemia Group B study 19805.
|
Clin Cancer Res
|
2005
|
2.19
|
|
15
|
Phase I study of low-dose interleukin-2, fludarabine, and cyclophosphamide for previously untreated indolent lymphoma and chronic lymphocytic leukemia.
|
Clin Cancer Res
|
2005
|
2.10
|
|
16
|
Low levels of miR-92b/96 induce PRMT5 translation and H3R8/H4R3 methylation in mantle cell lymphoma.
|
EMBO J
|
2007
|
2.08
|
|
17
|
Genome-wide methylation profiling in decitabine-treated patients with acute myeloid leukemia.
|
Blood
|
2012
|
1.97
|
|
18
|
Characterization of the TCL-1 transgenic mouse as a preclinical drug development tool for human chronic lymphocytic leukemia.
|
Blood
|
2006
|
1.92
|
|
19
|
The novel plant-derived agent silvestrol has B-cell selective activity in chronic lymphocytic leukemia and acute lymphoblastic leukemia in vitro and in vivo.
|
Blood
|
2009
|
1.83
|
|
20
|
Phase I trial of lenalidomide and CCI-779 in patients with relapsed multiple myeloma: evidence for lenalidomide-CCI-779 interaction via P-glycoprotein.
|
J Clin Oncol
|
2011
|
1.65
|
|
21
|
A phase I/II dose escalation study of apolizumab (Hu1D10) using a stepped-up dosing schedule in patients with chronic lymphocytic leukemia and acute leukemia.
|
Leuk Lymphoma
|
2009
|
1.58
|
|
22
|
A phase I trial of paclitaxel and trastuzumab in combination with interleukin-12 in patients with HER2/neu-expressing malignancies.
|
Mol Cancer Ther
|
2009
|
1.54
|
|
23
|
Mcl-1 is a relevant therapeutic target in acute and chronic lymphoid malignancies: down-regulation enhances rituximab-mediated apoptosis and complement-dependent cytotoxicity.
|
Clin Cancer Res
|
2007
|
1.52
|
|
24
|
Clinical and pharmacodynamic activity of bortezomib and decitabine in acute myeloid leukemia.
|
Blood
|
2012
|
1.51
|
|
25
|
Cyclophosphamide, alvocidib (flavopiridol), and rituximab, a novel feasible chemoimmunotherapy regimen for patients with high-risk chronic lymphocytic leukemia.
|
Leuk Res
|
2013
|
1.51
|
|
26
|
Computed tomography scans do not improve the predictive power of 1996 national cancer institute sponsored working group chronic lymphocytic leukemia response criteria.
|
J Clin Oncol
|
2007
|
1.45
|
|
27
|
Flavopiridol administered as a 24-hour continuous infusion in chronic lymphocytic leukemia lacks clinical activity.
|
Leuk Res
|
2005
|
1.44
|
|
28
|
TWIST2 demonstrates differential methylation in immunoglobulin variable heavy chain mutated and unmutated chronic lymphocytic leukemia.
|
J Clin Oncol
|
2005
|
1.39
|
|
29
|
The anticipated physician shortage: meeting the nation's need for physician services.
|
Am J Med
|
2009
|
1.38
|
|
30
|
Pentostatin, cyclophosphamide, and rituximab regimen in older patients with chronic lymphocytic leukemia.
|
Cancer
|
2007
|
1.38
|
|
31
|
Phase I study of oblimersen sodium, an antisense to Bcl-2, in untreated older patients with acute myeloid leukemia: pharmacokinetics, pharmacodynamics, and clinical activity.
|
J Clin Oncol
|
2005
|
1.33
|
|
32
|
ER stress and autophagy: new discoveries in the mechanism of action and drug resistance of the cyclin-dependent kinase inhibitor flavopiridol.
|
Blood
|
2012
|
1.27
|
|
33
|
Depsipeptide (FR901228) induces histone acetylation and inhibition of histone deacetylase in chronic lymphocytic leukemia cells concurrent with activation of caspase 8-mediated apoptosis and down-regulation of c-FLIP protein.
|
Blood
|
2003
|
1.26
|
|
34
|
Impact of prolonged infusions of the putative differentiating agent sodium phenylbutyrate on myelodysplastic syndromes and acute myeloid leukemia.
|
Clin Cancer Res
|
2002
|
1.23
|
|
35
|
Flavopiridol causes early mitochondrial damage in chronic lymphocytic leukemia cells with impaired oxygen consumption and mobilization of intracellular calcium.
|
Blood
|
2008
|
1.21
|
|
36
|
Dose escalation of lenalidomide in relapsed or refractory acute leukemias.
|
J Clin Oncol
|
2010
|
1.20
|
|
37
|
Phase I clinical and pharmacokinetic study of a novel schedule of flavopiridol in relapsed or refractory acute leukemias.
|
Haematologica
|
2010
|
1.17
|
|
38
|
Phase II trial of temsirolimus in patients with relapsed or refractory multiple myeloma.
|
Leuk Res
|
2009
|
1.16
|
|
39
|
Targeting Mutant BRAF in Relapsed or Refractory Hairy-Cell Leukemia.
|
N Engl J Med
|
2015
|
1.15
|
|
40
|
Pentostatin in steroid-refractory acute graft-versus-host disease.
|
J Clin Oncol
|
2005
|
1.15
|
|
41
|
Flavopiridol, fludarabine, and rituximab in mantle cell lymphoma and indolent B-cell lymphoproliferative disorders.
|
J Clin Oncol
|
2009
|
1.13
|
|
42
|
Development and validation of a sensitive liquid chromatography/mass spectrometry method for quantitation of flavopiridol in plasma enables accurate estimation of pharmacokinetic parameters with a clinically active dosing schedule.
|
J Chromatogr B Analyt Technol Biomed Life Sci
|
2008
|
1.12
|
|
43
|
Hyperglycemia in patients with acute myeloid leukemia is associated with increased hospital mortality.
|
Cancer
|
2007
|
1.11
|
|
44
|
Resistance to the translation initiation inhibitor silvestrol is mediated by ABCB1/P-glycoprotein overexpression in acute lymphoblastic leukemia cells.
|
AAPS J
|
2011
|
1.11
|
|
45
|
The novel deacetylase inhibitor AR-42 demonstrates pre-clinical activity in B-cell malignancies in vitro and in vivo.
|
PLoS One
|
2010
|
1.11
|
|
46
|
A LC-MS/MS method for the analysis of intracellular nucleoside triphosphate levels.
|
Pharm Res
|
2009
|
1.07
|
|
47
|
Phase 1 and pharmacodynamic studies of G3139, a Bcl-2 antisense oligonucleotide, in combination with chemotherapy in refractory or relapsed acute leukemia.
|
Blood
|
2002
|
1.05
|
|
48
|
Curcumin down-regulates DNA methyltransferase 1 and plays an anti-leukemic role in acute myeloid leukemia.
|
PLoS One
|
2013
|
1.05
|
|
49
|
Phase I study of GTI-2040, an antisense to ribonucleotide reductase, in combination with high-dose cytarabine in patients with acute myeloid leukemia.
|
Clin Cancer Res
|
2008
|
1.05
|
|
50
|
Combination immunotherapy of B-cell non-Hodgkin's lymphoma with rituximab and interleukin-2: a preclinical and phase I study.
|
Clin Cancer Res
|
2004
|
1.04
|
|
51
|
Dual targeting of the cyclin/Rb/E2F and mitochondrial pathways in mantle cell lymphoma with the translation inhibitor silvestrol.
|
Clin Cancer Res
|
2012
|
1.04
|
|
52
|
Phase I active immunotherapy with combination of two chimeric, human epidermal growth factor receptor 2, B-cell epitopes fused to a promiscuous T-cell epitope in patients with metastatic and/or recurrent solid tumors.
|
J Clin Oncol
|
2009
|
1.02
|
|
53
|
Potential of plant-derived natural products in the treatment of leukemia and lymphoma.
|
Curr Drug Targets
|
2010
|
1.02
|
|
54
|
Mcl-1 expression predicts progression-free survival in chronic lymphocytic leukemia patients treated with pentostatin, cyclophosphamide, and rituximab.
|
Blood
|
2008
|
1.00
|
|
55
|
Incidence of therapy-related myeloid neoplasia after initial therapy for chronic lymphocytic leukemia with fludarabine-cyclophosphamide versus fludarabine: long-term follow-up of US Intergroup Study E2997.
|
Blood
|
2011
|
0.99
|
|
56
|
Phase I trial of low dose decitabine targeting DNA hypermethylation in patients with chronic lymphocytic leukaemia and non-Hodgkin lymphoma: dose-limiting myelosuppression without evidence of DNA hypomethylation.
|
Br J Haematol
|
2010
|
0.99
|
|
57
|
Flavopiridol pharmacogenetics: clinical and functional evidence for the role of SLCO1B1/OATP1B1 in flavopiridol disposition.
|
PLoS One
|
2010
|
0.99
|
|
58
|
Flavopiridol treatment of patients aged 70 or older with refractory or relapsed chronic lymphocytic leukemia is a feasible and active therapeutic approach.
|
Haematologica
|
2012
|
0.99
|
|
59
|
Development and validation of a highly sensitive liquid chromatography/mass spectrometry method for simultaneous quantification of lenalidomide and flavopiridol in human plasma.
|
Ther Drug Monit
|
2008
|
0.98
|
|
60
|
A dose-finding, pharmacokinetic and pharmacodynamic study of a novel schedule of flavopiridol in patients with advanced solid tumors.
|
Invest New Drugs
|
2010
|
0.96
|
|
61
|
Silvestrol exhibits significant in vivo and in vitro antileukemic activities and inhibits FLT3 and miR-155 expressions in acute myeloid leukemia.
|
J Hematol Oncol
|
2013
|
0.96
|
|
62
|
Treatment of relapsed chronic lymphocytic leukemia: old and new therapies.
|
Semin Oncol
|
2006
|
0.95
|
|
63
|
Characterization of silvestrol pharmacokinetics in mice using liquid chromatography-tandem mass spectrometry.
|
AAPS J
|
2011
|
0.95
|
|
64
|
Flavopiridol in chronic lymphocytic leukemia: a concise review.
|
Clin Lymphoma Myeloma
|
2009
|
0.95
|
|
65
|
A pharmacokinetic/pharmacodynamic model of tumor lysis syndrome in chronic lymphocytic leukemia patients treated with flavopiridol.
|
Clin Cancer Res
|
2013
|
0.94
|
|
66
|
Therapeutic potential of the translation inhibitor silvestrol in hepatocellular cancer.
|
PLoS One
|
2013
|
0.93
|
|
67
|
PRMT5 is upregulated in malignant and metastatic melanoma and regulates expression of MITF and p27(Kip1.).
|
PLoS One
|
2013
|
0.92
|
|
68
|
Rituximab and 17-allylamino-17-demethoxygeldanamycin induce synergistic apoptosis in B-cell chronic lymphocytic leukaemia.
|
Br J Haematol
|
2007
|
0.91
|
|
69
|
Selective efficacy of depsipeptide in a xenograft model of Epstein-Barr virus-positive lymphoproliferative disorder.
|
J Natl Cancer Inst
|
2004
|
0.91
|
|
70
|
Complex karyotype predicts for inferior outcomes following reduced-intensity conditioning allogeneic transplant for chronic lymphocytic leukaemia.
|
Br J Haematol
|
2012
|
0.91
|
|
71
|
Flavopiridol in the treatment of chronic lymphocytic leukemia.
|
Curr Opin Oncol
|
2007
|
0.90
|
|
72
|
Validation of an LC-MS based approach for profiling histones in chronic lymphocytic leukemia.
|
Proteomics
|
2009
|
0.90
|
|
73
|
Expression of TCL-1 as a potential prognostic factor for treatment outcome in B-cell chronic lymphocytic leukemia.
|
Leuk Res
|
2007
|
0.88
|
|
74
|
Flavopiridol can be safely administered using a pharmacologically derived schedule and demonstrates activity in relapsed and refractory non-Hodgkin's lymphoma.
|
Am J Hematol
|
2013
|
0.87
|
|
75
|
Community-based phase II trial of PCR for CLL/SLL patients.
|
Cancer Biother Radiopharm
|
2007
|
0.87
|
|
76
|
Phase I study of azacitidine and bortezomib in adults with relapsed or refractory acute myeloid leukemia.
|
Leuk Lymphoma
|
2013
|
0.86
|
|
77
|
Lymphodepleting effects and safety of pentostatin for nonmyeloablative allogeneic stem-cell transplantation.
|
Transplantation
|
2003
|
0.85
|
|
78
|
Antibody therapy for chronic lymphocytic leukemia: a promising new modality.
|
Hematol Oncol Clin North Am
|
2004
|
0.84
|
|
79
|
A novel liposomal formulation of flavopiridol.
|
Int J Pharm
|
2008
|
0.84
|
|
80
|
A phase I study of prolonged infusion of triapine in combination with fixed dose rate gemcitabine in patients with advanced solid tumors.
|
Invest New Drugs
|
2012
|
0.84
|
|
81
|
Pentostatin and rituximab therapy for previously untreated patients with B-cell chronic lymphocytic leukemia.
|
Cancer
|
2010
|
0.83
|
|
82
|
Changing the way we think about chronic lymphocytic leukemia.
|
J Clin Oncol
|
2005
|
0.82
|
|
83
|
Phase I and pharmacokinetic study of erlotinib (OSI-774) in combination with docetaxel in squamous cell carcinoma of the head and neck (SSCHN).
|
Cancer Chemother Pharmacol
|
2010
|
0.82
|
|
84
|
In vivo quantification of active decitabine-triphosphate metabolite: a novel pharmacoanalytical endpoint for optimization of hypomethylating therapy in acute myeloid leukemia.
|
AAPS J
|
2012
|
0.80
|
|
85
|
A dose-finding and pharmacodynamic study of bortezomib in combination with weekly paclitaxel in patients with advanced solid tumors.
|
Cancer Chemother Pharmacol
|
2009
|
0.80
|
|
86
|
Pretreatment angiogenic cytokines predict response to chemoimmunotherapy in patients with chronic lymphocytic leukaemia.
|
Br J Haematol
|
2009
|
0.80
|
|
87
|
Pharmacokinetics and dose escalation of the heat shock protein inhibitor 17-allyamino-17-demethoxygeldanamycin in combination with bortezomib in relapsed or refractory acute myeloid leukemia.
|
Leuk Lymphoma
|
2013
|
0.80
|
|
88
|
KRN5500: a novel therapeutic agent with in vitro activity against human B-cell chronic lymphocytic leukemia cells mediates cytotoxicity via the intrinsic pathway of apoptosis.
|
Blood
|
2003
|
0.79
|
|
89
|
Standard pentostatin dose reductions in renal insufficiency are not adequate: selected patients with steroid-refractory acute graft-versus-host disease.
|
Clin Pharmacokinet
|
2013
|
0.77
|
|
90
|
A phase I/II study examining pentostatin, chlorambucil, and theophylline in patients with relapsed chronic lymphocytic leukemia and non-Hodgkin's lymphoma.
|
Ann Hematol
|
2006
|
0.77
|
|
91
|
A phase I dose escalation and pharmacodynamic study of SU5416 (semaxanib) combined with weekly cisplatin and irinotecan in patients with advanced solid tumors.
|
Onkologie
|
2013
|
0.76
|
|
92
|
Quantification of valproic acid and its metabolite 2-propyl-4-pentenoic acid in human plasma using HPLC-MS/MS.
|
J Chromatogr B Analyt Technol Biomed Life Sci
|
2006
|
0.76
|
|
93
|
Hematologic improvement after flavopiridol treatment of pentostatin and rituximab refractory hairy cell leukemia.
|
Leuk Lymphoma
|
2011
|
0.76
|
|
94
|
Phase I study of GTI-2040, a ribonucleotide reductase antisense, with high dose cytarabine in patients with relapsed/refractory acute myeloid leukemia.
|
Leuk Lymphoma
|
2013
|
0.76
|
|
95
|
Development and validation of a rapid and sensitive high-performance liquid chromatography-mass spectroscopy assay for determination of 17-(allylamino)-17-demethoxygeldanamycin and 17-(amino)-17-demethoxygeldanamycin in human plasma.
|
J Chromatogr B Analyt Technol Biomed Life Sci
|
2008
|
0.76
|
|
96
|
Reduced occurrence of tumor flare with flavopiridol followed by combined flavopiridol and lenalidomide in patients with relapsed chronic lymphocytic leukemia (CLL).
|
Am J Hematol
|
2015
|
0.75
|
|
97
|
A phase I and pharmacokinetic study of weekly oxaliplatin followed by paclitaxel in patients with solid tumors.
|
Clin Cancer Res
|
2008
|
0.75
|
|
98
|
Salvage therapy for relapsed chronic lymphocytic leukemia.
|
Expert Rev Hematol
|
2011
|
0.75
|